Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Timeline: Started 2004
U.S. locations: 115
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more

Conditions: Herpes Zoster
Interventions: Zostavax™; Biological
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Staphylococcus Aureus
Interventions: Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization; Drug
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: Not listed
Enrollment: 353,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 137
States / cities: Riverside, California • San Jose, California • Thousand Oaks, California + 103 more

Conditions: Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Interventions: ABC294640; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more

Conditions: Diarrhea, HIV Infections
Interventions: Octreotide; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: HIV Infections
Interventions: DTG/3TC FDC, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 4 more

Conditions: Corona Virus Infection
Interventions: COVID-19 testing; Diagnostic Test
Lead sponsor: Pinnacle Health Cardiovascular Institute; Network
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions: Neuromuscular Blocking Agents, Anesthetic Adjuncts; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: PrEPresent; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 26 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Hepatitis
Interventions: Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more

Conditions: Chronic Hepatitis C
Interventions: PSI-7977, Daclatasvir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Coronado, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Viral Hepatitis, Liver Fibrosis, Liver Disease, Hepatitis B, Hepatitis C
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Health Care, HIV Infections, Mouth Diseases
Interventions: Case-management linkage intervention; Behavioral
Lead sponsor: Lisa Metsch; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions: Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Uveitis
Interventions: Abatacept; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV, HIV-Infections, HIV-1-infection, HIV I Infection, HIV Lipodystrophy, HIV Infection Primary, HIV-Associated Lipodystrophy, HIV Disease Progression, Lipohypertrophy, Liver Diseases, NAFLD, NASH, Liver Fibrosis, Hepatic Fibrosis, Waist Circumference, BMI, Ectopic Fat, Liver Fat, Hepatic Steatosis
Interventions: Diagnostic Test, HIV Anti-retroviral Background Therapy; Diagnostic Test · Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Miami Beach, Florida + 4 more

Conditions: Non-infectious Anterior Uveitis
Interventions: ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more

Conditions: Zika Virus
Interventions: mRNA-1893, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 808 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas

Search by objective public record fields.

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

Mupirocin-Iodophor ICU Decolonization Swap Out Trial

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients

Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era

Avoiding Neuromuscular Blockers to Reduce Complications

PrEP2Prevent An Online PrEP Navigation and Activation Intervention

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases

Enhancing Oral Health Care Use by HIV Positive Individuals

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Prospective Study of Lymphoproliferative Diseases

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Abatacept in the Treatment of Uveitis

The Visceral Adiposity Measurement and Observation Study

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas